MetaVia Reports Positive Phase 1 Results for Obesity Drug DA-1726

Reuters

Nov 05

MetaVia Reports Positive Phase 1 Results for Obesity Drug DA-1726

MetaVia Inc. announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel dual oxyntomodulin analog agonist targeting GLP-1 and glucagon receptors, at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, GA. The Phase 1 study demonstrated favorable safety and tolerability, as well as a pharmacokinetic profile supporting once-weekly dosing. Meaningful reductions in body weight and waist circumference were observed after four weeks of treatment. Additionally, in pre-clinical diet-induced obesity mouse models, DA-1726 achieved comparable weight loss to pemvidutide and showed superior lipid-lowering effects. Results from an extended Phase 1 cohort evaluating a higher 48 mg dose are expected later in 2025. The data have not yet been presented and are scheduled for release at the upcoming conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15365) on November 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581619807"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581619807\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581619807?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 05:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581619807","market":"us","top_or_hot":-1,"title":"MetaVia Reports Positive Phase 1 Results for Obesity Drug DA-1726","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MetaVia Reports Positive Phase 1 Results for Obesity Drug DA-1726\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a>. announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel dual oxyntomodulin analog agonist targeting GLP-1 and glucagon receptors, at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, GA. The Phase 1 study demonstrated favorable safety and tolerability, as well as a pharmacokinetic profile supporting once-weekly dosing. Meaningful reductions in body weight and waist circumference were observed after four weeks of treatment. Additionally, in pre-clinical diet-induced obesity mouse models, DA-1726 achieved comparable weight loss to pemvidutide and showed superior lipid-lowering effects. Results from an extended Phase 1 cohort evaluating a higher 48 mg dose are expected later in 2025. The data have not yet been presented and are scheduled for release at the upcoming conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15365) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MetaVia Reports Positive Phase 1 Results for Obesity Drug DA-1726</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMetaVia Reports Positive Phase 1 Results for Obesity Drug DA-1726\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 05:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MetaVia Reports Positive Phase 1 Results for Obesity Drug DA-1726\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a>. announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel dual oxyntomodulin analog agonist targeting GLP-1 and glucagon receptors, at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, GA. The Phase 1 study demonstrated favorable safety and tolerability, as well as a pharmacokinetic profile supporting once-weekly dosing. Meaningful reductions in body weight and waist circumference were observed after four weeks of treatment. Additionally, in pre-clinical diet-induced obesity mouse models, DA-1726 achieved comparable weight loss to pemvidutide and showed superior lipid-lowering effects. Results from an extended Phase 1 cohort evaluating a higher 48 mg dose are expected later in 2025. The data have not yet been presented and are scheduled for release at the upcoming conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15365) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDLb7lGj7:1","article_id":"2581619807","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581619807","pubTimestamp":1762290220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MetaVia Inc. announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel dual oxyntomodulin analog agonist targeting GLP-1 and glucagon receptors, at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, GA. The Phase 1 study demonstrated favorable safety and tolerability, as well as a pharmacokinetic profile supporting once-weekly dosing. Meaningful reductions in body weight and waist circumference were observed after four weeks of treatment. Additionally, in pre-clinical diet-induced obesity mouse models, DA-1726 achieved comparable weight loss to pemvidutide and showed superior lipid-lowering effects. Results from an extended Phase 1 cohort evaluating a higher 48 mg dose are expected later in 2025. The data have not yet been presented and are scheduled for release at the upcoming conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MTVA":"MetaVia Inc"},"translate_title":"MetaVia报告肥胖药物DA-1726的积极1期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTVA":0.9},"content_text":"MetaVia Reports Positive Phase 1 Results for Obesity Drug DA-1726\n    \n\nMetaVia Inc. announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel dual oxyntomodulin analog agonist targeting GLP-1 and glucagon receptors, at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, GA. The Phase 1 study demonstrated favorable safety and tolerability, as well as a pharmacokinetic profile supporting once-weekly dosing. Meaningful reductions in body weight and waist circumference were observed after four weeks of treatment. Additionally, in pre-clinical diet-induced obesity mouse models, DA-1726 achieved comparable weight loss to pemvidutide and showed superior lipid-lowering effects. Results from an extended Phase 1 cohort evaluating a higher 48 mg dose are expected later in 2025. The data have not yet been presented and are scheduled for release at the upcoming conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15365) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}